Cargando…
Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness
Background: Fatigue is a frequent symptom in multiple sclerosis (MS) and often interrelated with depression and sleep disorders making symptomatic treatment decisions difficult. In the single-arm, observational phase IV TYNERGY study, relapsing–remitting MS patients showed a clinically meaningful de...
Autores principales: | Penner, Iris-Katharina, Sivertsdotter, Eva Catharina, Celius, Elisabeth G., Fuchs, Siegrid, Schreiber, Karen, Berkö, Sara, Svenningsson, Anders |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337367/ https://www.ncbi.nlm.nih.gov/pubmed/25755648 http://dx.doi.org/10.3389/fneur.2015.00018 |
Ejemplares similares
-
Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life Setting
por: Svenningsson, Anders, et al.
Publicado: (2013) -
Improving risk‐stratification of natalizumab‐associated PML
por: Tugemann, Bastian, et al.
Publicado: (2021) -
Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab
por: Berkovich, Regina, et al.
Publicado: (2021) -
Ecological momentary assessment of fatigue, sleepiness, and exhaustion in ESKD
por: Abdel-Kader, Khaled, et al.
Publicado: (2014) -
Cancer-related fatigue presenting with excessive daytime sleepiness
por: Balachandran, Diwakar D, et al.
Publicado: (2017)